Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth,

    Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly
   Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and
                                Bristol-Myers

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 20, 2013

NEW YORK, September 20, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), UnitedHealth Group Inc. (NYSE: UNH), Merck & Co., Inc.
(NYSE: MRK), Gilead Sciences, Inc. (NASDAQ: GILD), and Bristol-Myers Squibb
Co. (NYSE: BMY). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Pfizer Inc. Research Report

On September 11, 2013, Fitch Ratings Inc. (Fitch Ratings) affirmed Pfizer
Inc.'s (Pfizer) Issuer Default Rating (IDR) at 'A+', and provided a Stable
Rating Outlook. The rating actions apply to Pfizer's approximately $36.7
billion of consolidated debt outstanding as of June 30, 2013. Some of the key
rating drivers mentioned by Fitch were as follows: Fitch believes Pfizer's
narrowing focus on human branded pharmaceuticals will improve long-term
profitability and growth, offsetting the negative effect of a less-diversified
business model; the Company's patent cliff is becoming less steep as a smaller
percentage (approximately 20%) of branded revenues are exposed to patent
expiration in the next three years; one of Pfizer's at-risk branded products
(Enbrel) which Fitch expects will lose less market share to biosimilar
competition than the 80% to 90% that typically occurs with generic competition
to small molecule drug; Pfizer is making decent progress in developing and
commercializing a pipeline of the new drugs; and despite the Company's recent
drug launches, Fitch expects Pfizer will generate relatively flat organic
revenues through 2016. Also, Fitch anticipates Pfizer will generate strong
free cash flow and maintain solid liquidity during the intermediate term, and
continue to aggressively deploy cash towards acquisitions and share
repurchases. The Full Research Report on Pfizer Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]

--

UnitedHealth Group Inc. Research Report

On September 13, 2013, UnitedHealth Group Inc. (UnitedHealth) announced that
it was named to the Dow Jones Sustainability North America Index (DJSI NA) and
the Dow Jones Sustainability World Index (DJSI W). According to UnitedHealth,
it was recognized among the leading companies worldwide for economic,
environmental, and social excellence and sustainability performance, with a
strong focus on long-term shareholder value. In addition, UnitedHealth ranked
first in health care providers and services industry sector for corporate
citizenship and philanthropy, partnerships toward sustainable health care,
codes of conduct and compliance, and operational eco-efficiency. The Full
Research Report on UnitedHealth Group Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]

--

Merck & Co., Inc. Research Report

On September 17, 2013, Merck & Co., Inc. (Merck) announced that the Company
was named as one of the Working Mother 100 Best Companies for 2013, which
recognizes companies for their commitment to progressive workplace programs,
including female representation, compensation, child care, flexibility, time
off and leave, family friendly programs, and company culture. Dottie Brienza,
Chief Diversity Officer and Executive Talent Leader, Merck, said, "This award
recognizes Merck's commitment to fostering an environment where all employees,
including working parents and those who provide care for others, can
effectively integrate work and life, take care of themselves and their
families and reach their professional goals." According to the Company, this
recognition marks the 26th year that Merck was honored on the Working Mother
100 Best Companies List. The Full Research Report on Merck & Co., Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

Gilead Sciences, Inc. Research Report

On September 12, 2013, Gilead Sciences Inc. (Gilead) announced 48-week results
from a Phase 2 study (Study 102) evaluating tenofovir alafenamide (TAF), an
investigational once-daily single tablet regiment, for the treatment of HIV-1
infection. The Company revealed that at 48 weeks, a regimen of elvitegravir
150mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10mg was found to be similar
to Stribild (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir
disoproxil fumarate 300 mg) based on the percentage of patients with HIV RNA
levels less than 50 copies/mL, and was associated with more favorable renal
and bone safety markers. Norbert W. Bischofberger, PhD, Gilead's Executive
Vice President, Research and Development and Chief Scientific Officer, said,
"Based on these positive results, we believe that TAF has the potential to
become a key component of next-generation single tablet regimens in HIV
therapy. We are now completing enrollment of two Phase 3 clinical trials
comparing a TAF-based regimen to Stribild in patients new to HIV treatment,
and look forward to sharing initial results from these large-scale studies by
the end of 2014." The Full Research Report on Gilead Sciences, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Bristol-Myers Squibb Co. Research Report

On September 17, 2013, Bristol-Myers Squibb Co. (Bristol-Myers) announced that
its Board of Directors has declared a quarterly dividend of $0.35 per share on
the $0.10 par value Common Stock of the Company. The Company informed that
this quarterly dividend will be payable on November 1, 2013, to stockholders
of record at the close of business on October 4, 2013. In addition,
Bristol-Myers' Board of Directors declared a dividend of $0.50 per share on
the $2.00 Convertible Preferred Stock of the corporation, payable on December
2, 2013, to stockholders of record at the close of business on November 8,
2013. The Full Research Report on Bristol-Myers Squibb Co. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas: +1-310-496-8071 (North America)